BSX · Boston Scientific Corporation

Healthcare NYQ United States bostonscientific.com ↗
Val Gro Qua Mom Sta Cap P/S2.97 P/E Fwd P/E12.53 PEG0.63 52W –  RSI Target$62.41 (+45.3%) Beta0.57 Div
Loading chart…
RSI ()
Pattern Overlays
Loading patterns…
Medical Devices Marlborough, United States 59,000 employees
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Signal
Trend Strength
Price Levels
52-Week Range
52W Low 52W High
Position in Range
RSI (14)
0 · Oversold RSI 33 Overbought · 100
Signal Neutral
EMA Price Levels
Activity & Patterns
Volume Analysis
Momentum Dashboard
Detected Patterns
4Bullish
7Bearish
0Neutral

Key Signals 2

▲ Double Bottom Major reversal 2026-07-31 · $46.37
Two lows ~$42.23 — bullish reversal confirmed
Learn more →
▼ Head & Shoulders Major reversal 2026-09-10 · $44.15
H&S neckline ~$44.15 broken — major bearish reversal
Learn more →

Momentum Signals 9

▲ MACD Bullish Crossover 2026-05-18 · $55.92
▲ MACD Bullish Crossover 2026-06-10 · $48.34
▲ Bull Flag 2026-08-10 · $50.16
▼ MACD Bearish Crossover 2026-05-28 · $49.11

View overlays on the price chart via Overview tab → Pattern Overlays.

Next Earnings Oct 28, 2026
Beat Rate 100%
Consensus BUY
Analyst Upside +45.3%
EPS — History & Forecast
Estimate Beat Miss Forecast
Loading…
Revenue — History & Forecast
Revenue Forecast
Loading…
EPS Beat Rate
100% 8/8 quarters
Wall Street Consensus
BUY
26
5
BuyHoldSell
Price Target Range
$62.41 +45.3% upside
Low $44 High $94
Consensus Current price
Wall Street Analyst Ratings
Sort by
Firm Rating Change Action Date
Profitability
Gross Margin 69.19%Last 12 Months
Operating Margin 22.90%Last 12 Months
Return on Equity 15.34%Last 12 Months
Revenue Growth 7.50%Year over Year
Free Cash Flow 2.45BLast 12 Months
Free Cash Flow Yield Last 12 Months
Balance Sheet
Debt / Equity 50.15Most Recent Quarter
Current Ratio 1.24Most Recent Quarter
Cash 539.00MMost Recent Quarter
Total Debt 12.62BMost Recent Quarter
Net Debt Most Recent Quarter
How BSX Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
QuarterRevenueRev YoYGross Profit Op. IncomeNet IncomeNet YoY Gross %Op %Net %
Full Key Statistics
Valuation
Market Cap62.29B
Enterprise Value74.61B
Trailing P/E17.40
Forward P/E12.53
PEG Ratio (5yr)0.63
Price/Sales (ttm)2.97
Price/Book (mrq)2.49
EV/Revenue3.55
EV/EBITDA13.06
Share Statistics
Avg Vol (3m)20.00M
Shares Outstanding1.45B
Float1.44B
% Held by Insiders0.25%
% Held by Institutions94.76%
Short Ratio2.48
Short % of Float3.33%
Profitability
Gross Margin69.19%
Operating Margin (ttm)22.90%
Profit Margin17.50%
Return on Assets (ttm)6.19%
Return on Equity (ttm)15.34%
Income Statement
Revenue (ttm)21.00B
Revenue Growth (yoy)7.50%
Gross Profit (ttm)14.53B
EBITDA5.71B
Net Income (ttm)3.67B
Diluted EPS (ttm)2.47
EPS Growth (yoy)15.10%
Balance Sheet
Total Cash (mrq)539.00M
Total Debt (mrq)12.62B
Debt / Equity (mrq)50.15
Current Ratio (mrq)1.24
Book Value / Share17.23
Operating CF (ttm)4.53B
Free Cash Flow (ttm)2.45B
Trading & Dividends
Beta (5Y)0.57
50-Day MA46.94
200-Day MA65.96
Fwd Dividend YieldN/A
Payout Ratio0.00%

No dividend history available for BSX.

Ownership Breakdown
Institutional 94.76% Insider 0.25% Public 5.0%
Short Interest 3.33% of float
Moderate
Institutional 13F Holdings

Famous investors who disclosed a position in BSX in their latest SEC 13F filing.

Loading…
Insider Transactions
Date Insider Role Transaction Shares Price Value